Mesenchymal stromal cells improve early lymphocyte recovery and T cell reconstitution after autologous hematopoietic stem cell transplantation in patients with malignant lymphomas

Cell Immunol. 2015 Oct;297(2):80-6. doi: 10.1016/j.cellimm.2015.07.001. Epub 2015 Jul 7.

Abstract

Mesenchymal stromal cells (MSCs) possess a multi-lineage potential and immunoregulatory activities and provide a great potential in cell-based technologies. However, MSC suppressive activity raises concerns regarding the possible adverse effect of MSCs on the immune recovery. The influence of autologous MSC co-transplantation on recovery of T cell subsets in patients receiving autologous hematopoietic stem cell transplantation (AHSCT) for malignant lymphomas and multiple myeloma were characterized. Co-transplantation of MSCs improved lymphocyte recovery most effectively in patients with low input of hematopoietic stem cells or low absolute lymphocyte count in apheresis product. MSC co-transplantation improved early recovery of both memory and naive T cells with more prominent effect on naive CD4(+) T cells. Patients with MSC co-transplantation showed more effective reconstitution of recent thymic emigrants. These data indicate the positive impact of MSCs on immune reconstitution and note MSC co-transplantation is feasible to optimize the outcomes of AHSCT in malignant lymphoma patients.

Keywords: Autologous hematopoietic stem cell transplantation; Homeostatic proliferation; Immune reconstitution; Malignant lymphomas; Mesenchymal stromal cells.

Publication types

  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Cell Proliferation
  • Child
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Hodgkin Disease / immunology
  • Hodgkin Disease / pathology
  • Hodgkin Disease / therapy
  • Humans
  • Interleukin-2 / immunology
  • Lymphoma / immunology*
  • Lymphoma / pathology
  • Lymphoma / therapy*
  • Male
  • Mesenchymal Stem Cell Transplantation
  • Mesenchymal Stem Cells / immunology*
  • Middle Aged
  • Multiple Myeloma / immunology
  • Multiple Myeloma / pathology
  • Multiple Myeloma / therapy
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / pathology
  • Transplantation, Autologous
  • Young Adult

Substances

  • IL2 protein, human
  • Interleukin-2